Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 3/20 | 0.39 |
| ▸ | CEL | P19835 | 4/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19992007 | 0.80 | CYP2D6 (0.54) | CYP2D6CHRM2CHRM1EPHX1SIGMAR1 | |
| SCHEMBL15444322 | 0.80 | CYP2D6 (0.54) | CYP2D6CHRM2CHRM1EPHX1SIGMAR1 | |
| Decarboxylated Derivative SCHEMBL5183307 | 0.80 | CYP2D6 (0.54) | CYP2D6CHRM2CHRM1EPHX1SIGMAR1 | |
| SCHEMBL13893972 | 0.80 | CYP2D6 (0.54) | CYP2D6CHRM2CHRM1EPHX1SIGMAR1 | |
| SCHEMBL14417464 | 0.80 | CYP2D6 (0.54) | CYP2D6CHRM2CHRM1EPHX1SIGMAR1 | |
| SCHEMBL19099823 | 0.80 | CYP2D6 (0.54) | CYP2D6CHRM2CHRM1EPHX1SIGMAR1 | |
| SCHEMBL3536114 | 0.80 | CYP2D6 (0.54) | CYP2D6CHRM2CHRM1EPHX1SIGMAR1 | |
| Decarboxylated Derivative SCHEMBL9465 | 0.80 | — | — | |
| SCHEMBL22078896 | 0.80 | CYP2D6 (0.54) | CYP2D6CHRM2CHRM1EPHX1SIGMAR1 | |
| SCHEMBL18102722 | 0.80 | CYP2D6 (0.54) | CYP2D6CHRM2CHRM1EPHX1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358160-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6495576-B2 | N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | disclosed |
| US-20020165264-A1 | Aminal diones as potassium channel openers | ABBOTT LABORATORIES | 2002-11-07 | — | — | US | disclosed |
| US-20020147230-A1 | Aminal Diones as potassium channel openers | ABBOTT LABORATORIES | 2002-10-10 | — | — | US | disclosed |
| WO-2002062761-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147230-A1 | Aminal Diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | CYP2D6 569/4885DAO 449/4885CEL 4108/4885 |
| US-20020165264-A1 | Aminal diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | CYP2D6 569/4885DAO 449/4885CEL 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.